My Personalized Breast Screening
- Conditions
- Breast Screening
- Registration Number
- NCT03672331
- Lead Sponsor
- UNICANCER
- Brief Summary
MyPeBS is an international randomized, open-label, multicentric, study assessing the effectiveness of a risk-based breast cancer screening strategy (using clinical risk scores and polymorphisms) compared to standard screening (according to the current national guidelines in each participating country) in detecting stage 2 or higher breast cancers.
Women will be differentially screened for 4 years and then, after an end-of-study mammogram, they will return to the routine screening practice. The main study endpoint will be measured at the end of the four years of intervention.
Furthermore, follow up data will be collected for 15 years from study entry for evaluation of long-term cumulative breast cancer incidence and breast cancer-specific survival
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- Female
- Target Recruitment
- 53142
- Female (whether born female or not)
- Aged 40 to 70 years old (inclusive)
- Willing and able to comply with scheduled visits, laboratory tests, and other trial procedures
- Able to provide written informed consent obtained prior to performing any protocol-related procedures
- Sufficient understanding of any of the languages used in the study
- Affiliated to a social security/national healthcare system
- Personal history of breast carcinoma, either invasive or ductal carcinoma in situ (DCIS)
- Prior history of atypical breast lesion, lobular carcinoma in situ or chest wall irradiation
- Known condition or suspicion of a very high risk predisposition to breast cancer: germline mutation of BRCA1/2, PALB2, TP53 or equivalent
- History of bilateral mastectomy
- Recent abnormal breast finding under work-up (clinically suspect lesion or BI-RADS 4 or 5 image)
- Psychiatric or other disorders that are not compatible with compliance to the protocol requirements and follow-up
- Women who do not intend to be followed-up for 4 years
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Incidence rate of stage 2 and plus breast cancer (non-inferiority analysis) 4 years The study primary objective is to show non-inferiority of the risk-stratified screening strategy in terms of incidence rate of breast cancer of stage 2 and higher (2+), compared to standard screening.
- Secondary Outcome Measures
Name Time Method Socio-psychological characteristics of subjects 4 years Socio-psychological characteristics will be evaluated using study specific questions concerning comprehension, information-seeking behavior, satisfaction and socio-demographic and economic status
Incidence rate of stage 2 and plus breast cancer (superiority analysis) 4 years The key secondary objective, if non-inferiority is shown, is to demonstrate superiority of the risk-based screening arm to reduce the incidence rate of stage 2+ breast cancer, compared to standard screening.
Rate of morbidity in each arm 4 years Morbidity is defined as false positive imaging findings and benign breast biopsies
Subject anxiety in response to risk evaluation 4 years Subject anxiety will be evaluated using the State-Trait Anxiety Inventory (STAI) questionaire, and compared between treatment arms
Rate of false positive imaging findings and benign breast biopsies in women classified at low risk in risk-based arm 4 years Comparison of cost-effectiveness of each strategy 4 years Crude costs, defined as full real costs per stage 2 cancer diagnosis, will be estimated in each arm. The cost-effectiveness of mammographic screening will be calculated by comparing estimated life-years and costs of breast cancer in each arm
Estimates of the rate of detection of clinically non-significant tumours (overdiagnosis) in each study arm 15 years Overdiagnosed breast cancer cases are defined as cancers that would never have been detected clinically, if women had not been screened. Differential overdiagnosis will be measured comparing the cumulative incidence of breast cancer in each arm 15 years after the end of the interventional period of the study.
Rate of breast cancers identified at second reading in each arm 4 years Subject quality of life 4 years Subject quality of life will be evaluated using the EQ-5D quality of life questionnaire
Incidence of stage-specific breast cancer in each arm (including DCIS) 4 years Comparison of the overall incidence of breast cancer detected in each arm according to AJCC stage
10- and 15-year breast cancer specific survival in MyPeBS and in a combined analysis of the Wisdom and MyPeBS studies 15 years Rate of false negative images and interval cancers in each arm 4 years False negative images: in case of diagnosis of breast cancer in women whose last screening images (including mammogram +/- US and MRI) were considered as Breast Imaging- Reporting and Data System 1 or 2 (BI-RADS 1 or 2) at 6 months maximum before diagnosis. Interval cancers are defined as a breast cancers diagnosed between a negative screening episode - \[mammogram classified as normal (BI-RADS ACR 1 or 2 or equivalent) or abnormal mammogram but negative assessment\] and the next planned mammogram
Detection rate of stage 2+ breast cancer in women who had screening tomosynthesis (where and when available) and the rate without tomosynthesis 4 years Incidence of stage 2 + breast cancer in each arm, in women aged 40-49 at inclusion 4 years Incidence of all stage and stage 2 + breast cancers at 10- and 15-year follow-up 15 years
Trial Locations
- Locations (6)
Institut Jules Bordet
🇧🇪Bruxelles, Belgium
Gustave roussy
🇫🇷Villejuif, France
Assuta Medical Center Ramat HaHayal
🇮🇱Tel Aviv, Israel
AUSL Reggio Emilia
🇮🇹Reggio Emilia, Emilia, Italy
Marta Romản
🇪🇸Barcelona, Spain
Cambridge University Hospitals NHS Foundation Trust
🇬🇧Cambridge, Cambridgeshire, United Kingdom
Institut Jules Bordet🇧🇪Bruxelles, Belgium